In a significant stride towards combating tuberculosis (TB), Revvity unveiled its pioneering T-SPOT.TB test for latent TB screening during the 46th MICROCON at King George’s Medical University in Lucknow. The test, introduced by Shripad Joshi, President of India & South Asia at Revvity, was highlighted for its pivotal role in detecting latent TB, deemed crucial for India’s health mission.

Dr. Amita Jain, Head of Microbiology, and Dr. Surya Kant, Head of Respiratory Medicine at Revvity, underscored the significance of innovative screening tools in achieving India's TB eradication mission.

Revvity’s T-SPOT.TB test, an FDA-approved IGRA utilizing ELISPOT technology, promises reproducible results and reliable detection, even among challenging groups like the immunosuppressed. Notably, endorsed by the World Health Organization (WHO), the test doesn't cross-react with the widely used BCG vaccine in India, ensuring accurate results by normalizing T-cell counts, crucial for populations with weakened immune systems.

President Shripad Joshi emphasized collaboration with the Indian healthcare sector to integrate the T-SPOT.TB test, aiming to make latent TB screening accessible and affordable for all. With a staggering 40 percent of the population affected, this reliable single-visit test addresses a significant health concern, according to Revvity.

Joshi asserted, “Detecting infection before it progresses is paramount. We are committed to supporting the Government’s mission.”

Dr. Surya Kant highlighted the importance of early detection through widespread testing in preventing latent TB progression, while Dr. Amita Jain assured the test’s reliability, especially in high-risk groups with weakened immune systems.

The launch of Revvity’s T-SPOT.TB test marks a pivotal advancement in TB screening, offering hope in the fight against this prevalent disease and aligning with national health initiatives to curb its impact.